
FDA Approves ConcizuTrace™ ELISA Companion Diagnostic for 2024 Concizumab Therapy in Hemophilia
The National Bleeding Disorders Foundation (NBDF) shared a post on X:
”The FDA has approved the ConcizuTrace™ ELISA Companion Diagnostic test to measure concizumab-mtci levels in hemophilia A and B patients.’
To learn more about this advancement, follow the link.
The U.S. Food and Drug Administration (FDA) has approved the ConcizuTrace™ ELISA Companion Diagnostic, a test designed to measure plasma levels of concizumab-mtci in patients with hemophilia A or B.
Concizumab-mtci is a subcutaneous therapy indicated for routine prophylaxis to prevent or reduce bleeding episodes in adult and pediatric patients (≥12 years) with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.
The approval of this companion diagnostic marks a significant step in personalizing treatment, enabling clinicians to monitor drug exposure and potentially optimize therapeutic outcomes.
Never miss the important in the World of Hemophilia, read Hemostasis Today.
-
Aug 26, 2025, 10:02Women’s Equality Day: HFA Recognizes Women with Bleeding Disorders
-
Aug 26, 2025, 09:59Rare Disease Advisor – RBC Rheology Alterations in Hemophilia with Arthropathy
-
Aug 26, 2025, 09:57HFA Supports Future Planning for People with Bleeding Disorders
-
Aug 26, 2025, 09:56Phillip Taboada: TXA Shows No Added Benefit in Aquablation
-
Aug 26, 2025, 09:50A Global Collaboration: PERT Consortium Expands Reach in PE Care
-
Aug 26, 2025, 09:54TSUBASA Study: Emicizumab Improves Daily Life and Motivation in Hemophilia A Patients
-
Aug 26, 2025, 09:38Advancing CAT Care: New Insights on Extended Anticoagulation from Gerotziafas and Tafur
-
Aug 26, 2025, 09:35Alexander Mazein: Innovative Insights into Cytokine Release Syndrome via a Novel Explorable Model for Biotherapeutics and Cellular Therapies
-
Aug 25, 2025, 10:40Maria Filomena Ruberto on The Hypercoagulable State
-
Aug 25, 2025, 09:19Parham Dastjerdi – Clonal Hematopoiesis and VTE Risk
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Aug 18, 2025, 23:50Safe and Efficient Thrombectomy with Artix System: Clinical Insights from Neil Desai and Colleagues
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Aug 26, 2025, 09:42David McIntosh Highlights Global Blood Shortages and Fresh vs Stored RBCs
-
Aug 23, 2025, 07:48Protecting Heart and Brain Health: Stroke Prevention in Women with Bleeding Disorders: NBDF
-
Aug 21, 2025, 15:08Global Variations in Blood Collection: What Explains the Differences?
-
Aug 20, 2025, 13:33Askat's Life with Hemophilia A after Access to Prophylactic Treatment Through the WFH Humanitarian Aid Program
-
Aug 19, 2025, 17:22Louise Bannon Encourages You to Support World Thrombosis Day!